Eli Lilly And Co (NYSE:LLY) Stock Position Trimmed by Wheatland Advisors Inc.

Wheatland Advisors Inc. reduced its stake in Eli Lilly And Co (NYSE:LLY) by 1.3% during the second quarter, HoldingsChannel reports. The firm owned 28,841 shares of the company’s stock after selling 374 shares during the period. Eli Lilly And Co comprises about 2.4% of Wheatland Advisors Inc.’s portfolio, making the stock its 10th biggest holding. Wheatland Advisors Inc.’s holdings in Eli Lilly And Co were worth $3,195,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Meridian Wealth Management LLC purchased a new stake in Eli Lilly And Co in the first quarter valued at approximately $38,000. Ellis Investment Partners LLC purchased a new stake in Eli Lilly And Co in the first quarter valued at approximately $39,000. Manchester Financial Inc. purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $40,000. Litman Gregory Asset Management LLC purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $47,000. Finally, Personal Wealth Partners purchased a new stake in Eli Lilly And Co in the second quarter valued at approximately $53,000. 78.92% of the stock is currently owned by institutional investors and hedge funds.

NYSE LLY traded down $2.10 on Friday, reaching $109.51. 2,746,327 shares of the company’s stock traded hands, compared to its average volume of 3,804,582. Eli Lilly And Co has a 12 month low of $103.65 and a 12 month high of $132.13. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87. The stock has a 50-day simple moving average of $110.45 and a 200 day simple moving average of $117.75. The stock has a market cap of $107.75 billion, a PE ratio of 19.73, a P/E/G ratio of 1.97 and a beta of 0.19.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The business had revenue of $5.64 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business earned $1.48 earnings per share. The business’s quarterly revenue was up .9% on a year-over-year basis. As a group, analysts anticipate that Eli Lilly And Co will post 5.72 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be issued a $0.645 dividend. This represents a $2.58 annualized dividend and a dividend yield of 2.36%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s dividend payout ratio is 46.49%.

In other news, CFO Joshua L. Smiley bought 426 shares of the business’s stock in a transaction dated Wednesday, June 5th. The shares were purchased at an average price of $118.03 per share, for a total transaction of $50,280.78. Following the completion of the acquisition, the chief financial officer now owns 30,410 shares of the company’s stock, valued at $3,589,292.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Michael J. Harrington sold 16,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the completion of the transaction, the vice president now owns 110,300 shares in the company, valued at approximately $12,874,216. The disclosure for this sale can be found here. 0.11% of the stock is currently owned by company insiders.

A number of equities research analysts recently weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Eli Lilly And Co in a research note on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. TheStreet cut shares of Eli Lilly And Co from a “b+” rating to a “c+” rating in a research report on Thursday, May 9th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $143.00 price target on shares of Eli Lilly And Co in a research report on Tuesday, April 30th. Nine equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $123.49.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.